Active Funding Opportunity Announcements (FOAs) for All NICHD

NICHD issues and participates in various FOAs to support research activities and training.

Investigator-Initiated (Unsolicited) Projects

To submit unsolicited or investigator-initiated applications, use the appropriate NIH Parent Announcement.

Active FOAs for NICHD

Please note: The following FOAs are sorted by date, from most recent to oldest. Select a table heading to change how to sort and display the FOAs.

Announcement Number Submissions Date(s) Expiration Date Activity Code(s) Title
PA-18-838 Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

The first standard application due date for this FOA is October 5, 2018.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
September 8, 2021 R01 Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 - Clinical Trial Optional)
PA-18-839 Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

The first standard application due date for this FOA is October 16, 2018.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
September 8, 2021 R21 Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R21 Clinical Trial Optional)
PAR-18-835 November 7, 2018; November 7, 2019, November 6, 2020 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
November 7, 2020 R01 Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
PAR-18-836 November 7, 2018; November 7, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
November 7, 2020 R21 Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
PAR-18-831 November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020,
June 3, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
June 4, 2021 R21 The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed)
PAR-18-830 November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
June 4, 2021 R01 The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)
PAR-18-822 September 4, 2018, September 4, 2019, September 4, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
September 5, 2020 R01 Approaches for Understanding Disease Mechanisms and Improving Outcomes in TB Meningitis (TBM) (R01 Clinical Trial Not Allowed)
PAR-18-813 The first due date is August 1, 2018;Standard dates apply after that, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
May 8, 2021 K99/R00 BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Clinical Trial Required)
PAR-18-814 The first due date is August 1, 2018; Standard dates apply after that, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
May 8, 2021 K99/R00 BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
PA-18-790 Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

The first standard application due date for this FOA is October 5, 2018.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
September 8, 2021 R01 Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R01 - Clinical Trial Optional)
PA-18-791 Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

The first standard application due date for this FOA is October 16, 2018.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
September 8, 2021 R03 Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)
RFA-MH-19-136 September 27, 2018; September 6, 2019; September 9,2020
, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
September 10, 2020 R01 BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)
PAR-18-766 Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
September 8, 2021 R01 Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities (R01 - Clinical Trial Optional)
RFA-NS-18-030 July 3, 2018; N?o?v?e?m?b?e?r? ?6, 2018; July 3, 2019; November 6, 2019; July 1, 2020; November 10, 2020by 5:00 PM local time of applicant organization.All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. November 11, 2020 R01 BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)
PAR-18-747 June 14, 2018, November 14, 2018, June 14, 2019, November 14, 2019, June 15, 2020, November 13, 2020 by 5:00 PM local time of applicant organization. November 14, 2020 R01 Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R01 Clinical Trial Optional)
PAR-18-745 June 14, 2018, November 14, 2018, June 14, 2019, November 14, 2019, June 15, 2020 and November 13, 2020 by 5:00 PM local time of applicant organization. November 14, 2020 R21 Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional)
PA-18-728 Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
January 8, 2021 R21 Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)
PA-18-729 Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
January 8, 2021 R01 Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional)
PA-18-720 Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. September 8, 2020 R21 Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)
PAR-18-714 Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. May 8, 2021 R15 Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)
top of pageBACK TO TOP